Is your quality system built for 2026’s new regulatory reality?
The life sciences industry has always operated under pressure to stay ahead of regulatory change. But 2026 has raised the …
Post
-
-
Alkermes releases nine-month data as OX2R race heats up
Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has shown continued benefit nine months after the start of treatment in …
-
NewAmsterdam’s cholesterol-lowering therapy shows Alzheimer’s promise
NewAmsterdam’s low-density lipoprotein (LDL) cholesterol-lowering therapy, obicetrapib, has shown promise in diminishing a key biomarker of Alzheimer’s disease – potentially …
-
“Hub-and-spoke” drug manufacturing set to benefit from new FDA rule
The US Food and Drug Administration (FDA) has proposed a new rule that will simplify the registration step for certain …
-
GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial
GSK’s bet on Hansoh Pharmaceutical’s antibody-drug conjugate (ADC) seems to be paying off as the drug met all its endpoints …
-
Serina concludes sentinel dosing in Phase Ib trial’s Cohort 1
Serina Therapeutics has completed sentinel dosing in Cohort 1 of its ongoing Phase Ib registrational trial assessing SER-252 in adults …
-
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy …
-
Keeping pace with generative AI in pharmaceutical and healthcare organisations
Increasingly, generative AI is transforming how that information is analysed, summarised and shared. According to 2026 research by the Copyright Licensing …
-
Roche culls development of two Huntington’s disease programmes
Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase …
-
Ipsen set to rival Botox after duo of Phase III migraine wins
Ipsen Pharmaceuticals’ Dysport (abobotulinumtoxinA), a Botox (onabotulinumtoxinA) competitor, could be on track for a label expansion after the drug posted …
-
Forte Biosciences reports positive results from Phase Ib trial for vitiligo
Forte Biosciences has reported positive results from its double-blind, placebo-controlled Phase Ib trial assessing FB102 for vitiligo. The study followed patients …
-
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
Quoin Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application …
-
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure
Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a …
-
Keenova seeks Xiaflex expansion on late-stage rare disease win
Keenova Therapeutics is hoping to step into a new market with Xiaflex (collagenase clostridium histolyticum), after the drug netted a …
-
Satellos’ oral DMD drug improves arm movement after six months in Phase II
Satellos Bioscience’s oral Duchenne muscular dystrophy (DMD) drug has increased upper limb activity in four patients in a Phase II …
